Kardiovaskuläre Nebenwirkungen onkologischer Immuntherapien

Angesichts des zunehmenden Spektrums onkologischer Therapieoptionen und dem längeren Überleben der Tumorpatienten treten vermehrt kardiovaskuläre Nebenwirkungen auf. Präventive Maßnahmen und die Früherkennung der kardiologischen Toxizität werden mit der Weiterentwicklung der onkologischen Therapiemöglichkeiten immer wichtiger. Folgend werden spezifische kardiovaskuläre Nebenwirkungen erläutert und therapeutische Algorithmen benannt.

Schlüsselwörter

Immuntherapie - Onkologie - Kardiotoxizität - Myokarditis - T-Zell-Therapie

• Literatur

• 1 Totzeck M, Lutgens E, Neilan TG. Are we underestimating the potential for cardiotoxicity related to immune checkpoint inhibitors?. Eur Heart J 2020; 42: 1632-1635
• 2 Totzeck M, Schuler M, Stuschke M. et al. Cardio-oncology – strategies for management of cancer-therapy related cardiovascular disease. Int J Cardiol 2019; 280: 163-175
• 3 Moslehi JJ. Cardiovascular Toxic Effects of Targeted Cancer Therapies. N Engl J Med 2016; 375: 1457-1467
• 4 Rassaf T, Totzeck M, Backs J. et al. Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology. Clin Res Cardiol 2020; 109: 1197-1222
• 5 Totzeck M, Michel L, Lin Y. et al. Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies. Eur Heart J 2022; 43: 1928-1940
• 6 Michel L, Helfrich I, Hendgen-Cotta UB. et al. Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy. Eur Heart J 2022; 43: 316-329
• 7 Palaskas N, Lopez-Mattei J, Durand JB. et al. Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. J Am Heart Assoc 2020; 9: e013757
• 8 Michel L, Rassaf T, Totzeck M. Cardiotoxicity from immune checkpoint inhibitors. Int J Cardiol Heart Vasc 2019; 25: 100420
• 9 Mahmood SS, Fradley MG, Cohen JV. et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol 2018; 71: 1755-1764
• 10 Michel L, Totzeck M, Lehmann L. et al. Emerging role of immune checkpoint inhibitors and their relevance for the cardiovascular system. Herz 2020; 45: 645-651
• 11 Brahmer JR, Lacchetti C, Schneider BJ. et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018; 36: 1714-1768
• 12 Rassaf T, Totzeck M, Backs J. et al. Onkologische Kardiologie. Kardiologe 2020; 14: 267-293
• 13 Bonaca MP, Olenchock BA, Salem JE. et al. Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology. Circulation 2019; 140: 80-91
• 14 Michel L, Rassaf T, Totzeck M. Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity. J Thorac Dis 2018; 10: S4282-S4295
• 15 Collet JP, Thiele H, Barbato E. et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021; 42: 1289-1367
• 16 Thavendiranathan P, Zhang L, Zafar A. et al. Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor-Associated Myocarditis. J Am Coll Cardiol 2021; 77: 1503-1516
• 17 McDonagh TA, Metra M, Adamo M. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42: 3599-3726
• 18 Stein-Merlob AF, Rothberg MV, Ribas A. et al. Cardiotoxicities of novel cancer immunotherapies. Heart 2021; 107: 1694-1703
• 19 Lee DH, Fradley MG. Cardiovascular Complications of Multiple Myeloma Treatment: Evaluation, Management, and Prevention. Curr Treat Options Cardiovasc Med 2018; 20: 19
• 20 Burns EA, Gentille C, Trachtenberg B. et al. Cardiotoxicity Associated with Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Recognition, Risk Factors, and Management. Diseases 2021; 9: 20
• 21 Gökbuget N, Dombret H, Bonifacio M. et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood 2018; 131: 1522-1531
• 22 Przepiorka D, Ko CW, Deisseroth A. et al. FDA Approval: Blinatumomab. Clin Res Cardiol 2015; 21: 4035-4039
• 23 Kantarjian H, Stein A, Gökbuget N. et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med 2017; 376: 836-847
• 24 Subramanian S, Bates SE, Wright JJ. et al. Clinical Toxicities of Histone Deacetylase Inhibitors. Pharmaceuticals (Basel) 2010; 3: 2751-2767